# Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

> **NCT06422858** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Tegafur-gimeracil-oteracil potassium capsule(S1)
- **RADIATION:** Radiotherapy
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06422858
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-04
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06422858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06422858, "Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06422858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*